TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODIES

The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KYRYCH SADILKOVA, LENKA, BEERLI, ROGER, IVA, VALENTOVA, WALDMEIER, LORENZ, MOEBIUS, ULRICH, BAMMERT, LUKAS, HOSKOVA, SIMONA
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention provides tumor specific anti-CLDN18.2 antibodies or fragments thereof. The antibodies or fragments thereof exhibit increased binding to tumor tissue expressing CLDN 18.2 over healthy tissue expressing CLDN18.2. Further, the antibodies do not exhibit cross-reactivity to CLDN18.1. The invention also provides nucleic acids, vectors, host cells and medical uses. L'invention concerne des anticorps anti-CLDN18.2 spécifiques d'une tumeur ou des fragments de ceux-ci. Les anticorps ou fragments de ceux-ci présentent une liaison plus élevée au tissu tumoral exprimant CLDN 18,2 qu'au tissu sain exprimant CLDN 18.2. En outre, les anticorps ne présentent pas de réactivité croisée à CLDN 18.1. L'invention concerne également des acides nucléiques, des vecteurs, des cellules hôtes et des utilisations médicales.